An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Chen, Xiao-Wu, He, Zhi-Xu, Zhou, Zhi-Wei, Yang, Tianxin, Zhang, Xueji, Yang, Yin-Xue, Duan, Wei and Zhou, Shu-Feng 2015, An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus., Clinical and experimental pharmacology and physiology, vol. 42, no. 12, pp. 1225-1238, doi: 10.1111/1440-1681.12469. Attached Files Name Description MIMEType Size Downloads Title An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Author(s) Chen, Xiao-Wu He, Zhi-Xu Zhou, Zhi-Wei Yang, Tianxin Zhang, Xueji Yang, Yin-Xue Duan, Wei orcid.org/0000-0001-5782-9184 Zhou, Shu-Feng Journal name Clinical and experimental pharmacology and physiology Volume number 42 Issue number 12 Start page 1225 End page 1238 Total pages 14 Publisher Wiley Place of publication London, Eng. Publication date 2015-12 ISSN 1440-1681 Keyword(s) DPP-4 inhibitor adverse effect alogliptin combination therapy pharmacokinetics type 2 diabetes (T2DM) Science & Technology Life Sciences & Biomedicine Pharmacology & Pharmacy Physiology GLUCAGON-LIKE PEPTIDE-1 INCRETIN-BASED THERAPIES LONG-TERM EXTENSION INITIAL COMBINATION THERAPY INADEQUATE GLYCEMIC CONTROL PLACEBO-CONTROLLED TRIAL DRUG-NAIVE PATIENTS BETA-CELL FUNCTION DOUBLE-BLIND JAPANESE PATIENTS Summary Alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor that is a class of relatively new oral hypoglycaemic drugs used in patients with type 2 diabetes (T2DM), can be used as monotherapy or in combination with other anti-diabetic agents, including metformin, pioglitazone, sulfonylureas and insulin with a considerable therapeutic effect. Alogliptin exhibits favorable pharmacokinetic and pharmacodynamic profiles in humans. Alogliptin is mainly metabolized by cytochrome P450 (CYP2D6) and CYP3A4. Dose reduction is recommended for patients with moderate or worse renal impairment. Side effects of alogliptin include nasopharyngitis, upper-respiratory tract infections and headache. Hypoglycaemia is seen in about 1.5% of the T2DM patients. Rare but severe adverse reactions such as acute pancreatitis, serious hypersensitivity including anaphylaxis, angioedema and severe cutaneous reactions such as Stevens-Johnson syndrome have been reported from post-marketing monitoring. Pharmacokinetic interactions have not been observed between alogliptin and other drugs including glyburide, metformin, pioglitazone, insulin and warfarin. The present review aimed to update the clinical information on pharmacodynamics, pharmacokinetics, adverse effects and drug interactions, and to discuss the future directions of alogliptin. Language eng DOI 10.1111/1440-1681.12469 Field of Research 111502 Clinical Pharmacology and Therapeutics 0606 Physiology 1115 Pharmacology And Pharmaceutical Sciences 1116 Medical Physiology Socio Economic Objective 920104 Diabetes HERDC Research category C1 Refereed article in a scholarly journal ERA Research output type C Journal article Copyright notice ©2015, Wiley Persistent URL http://hdl.handle.net/10536/DRO/DU:30080598 Document type: Journal Article Collections: Faculty of Health School of Medicine Related Links Link Description Connect to Elements publication management system Go to link with your DU access privileges   Connect to published version Go to link with your DU access privileges   Publisher URL Go to link with your DU access privileges     Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved. Versions Version Filter Type Fri, 08 Jan 2016, 10:28:17 EST Wed, 20 Jul 2016, 11:21:18 EST Thu, 21 Jul 2016, 05:00:38 EST Thu, 21 Jul 2016, 06:09:37 EST Thu, 21 Jul 2016, 09:46:56 EST Thu, 21 Jul 2016, 09:47:50 EST Thu, 21 Jul 2016, 09:48:33 EST Thu, 21 Jul 2016, 09:57:54 EST Wed, 12 Oct 2016, 14:39:02 EST Wed, 01 Mar 2017, 07:40:09 EST Fri, 31 Jan 2020, 13:13:16 EST Sun, 17 Jul 2022, 07:36:59 EST Filtered Full Citation counts:   Cited 14 times in TR Web of Science Cited 13 times in Scopus Search Google Scholar Access Statistics: 529 Abstract Views, 1 File Downloads  -  Detailed Statistics Created: Wed, 20 Jul 2016, 11:21:18 EST